Tasly’s wholly-owned subsidiary, Memantine Hydrochloride Sustained-Release Capsules Obtained Drug Registration Certificate

On December 21, Tasly issued an announcement stating that its wholly-owned subsidiary, Diyi Pharmaceutical, had issued the Drug Registration Certificate for Memantine Hydrochloride Sustained Release Capsules approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer’s.

Memantine Hydrochloride Sustained-Release Capsules applied for CDE technical review in July 2019, with acceptance numbers CYHS1900507 and CYHS1900508 respectively, and recently obtained the "Drug Registration Certificate" (certificate numbers: 2021S01253, 2021S01254) approved and issued by the State Food and Drug Administration

Memantine hydrochloride is a new type of N-methyl-D-aspartate (NMDA) receptor antagonist, which can protect nerve cell function and promote the recovery of cognitive function

The "Guidelines for the Diagnosis and Treatment of Alzheimer's Disease Dementia (2020 Edition)" shows that with the aging of the population in China, dementia has become a common disease of the elderly, of which Alzheimer's disease (Alzheimer's disease, AD) dementia accounts for 60%- 80%

Memantine Hydrochloride-related products in domestic public and county-level public cities in China have sales of 594 million yuan in 2020 (both ordinary tablets and oral liquids)